高级检索

    CXCL8高表达对结肠癌的诊断及预后预测价值

    The diagnostic and prognostic value of high expression of CXCL8 in colon cancer

      摘要
    • 摘要: 目的 明确趋化因子配体8(CXCL8)在结肠癌中的表达特征,系统评估其诊断价值、临床关联及预后预测效能,探讨其通过免疫微环境调控肿瘤进展的机制,为结肠癌诊疗提供新的生物标志物。方法 整合 TCGA 数据库中478 例结肠癌及 41 例正常组织的转录组测序(RNA-Seq)数据,结合徐州医科大学第二附属医院30对结肠癌及癌旁组织临床样本,采用生物信息学、免疫组化、细胞实验及预后模型分析CXCL8在结肠癌中的表达、功能及临床意义。结果 TCGA数据库中结肠癌组织CXCL8 mRNA水平较癌旁配对组织显著升高(P<0.001)。免疫组化显示结肠癌组织CXCL8高表达率(43.33%,13/30)显著高于癌旁组织(13.33%,4/30,χ2=4.948,P=0.026)。受试者工作特征(ROC)曲线证实CXCL8诊断结肠癌效能良好曲线下面积(AUC)=0.89,95%CI:0.85～0.93,对Ⅲ—Ⅳ期患者诊断价值更高(AUC=0.92)。CXCL8高表达组总生存期(HR=1.79,P<0.001)及疾病特异性生存期(HR=2.21,P<0.001)显著缩短。多因素Cox回归分析显示CXCL8高表达是结肠癌患者预后的独立危险因素(HR=1.93, 95%CI: 1.04~3.58, P=0.037)。基于CXCL8的列线图预测结肠癌患者1、3、5年生存率的AUC分别为0.837、0.821、0.792。结论 CXCL8在结肠癌组织中高表达,兼具诊断与独立预后预测价值,通过重塑免疫微环境及激活促癌通路促进结肠癌进展,可作为结肠癌精准诊疗的潜在生物标志物。

       

      Abstract: Objective To clarify the expression characteristics of CXCL8 in colon cancer, systematically assess its diagnostic value, clinical relevance, and prognostic predictive efficacy, and explore its mechanism in regulating tumor progression through the immune microenvironment, providing a new biomarker for the diagnosis and treatment of colon cancer. Methods RNA-Seq data from 478 colon cancer samples and 41 normal tissues in the TCGA database were integrated with clinical samples of 30 pairs of colon cancer and adjacent tissues from the Second Affiliated Hospital of Xuzhou Medical University. Bioinformatics, immunohistochemistry, cell experiments, and prognostic model analyses were conducted to evaluate the expression, function, and clinical significance of CXCL8 in colon cancer. Results In the TCGA database, CXCL8 mRNA levels in cancer tissues were significantly higher in paired colon cancer and adjacent tissues (P<0.001). Immunohistochemistry results revealed that the high expression rate of CXCL8 (score>4) in cancer tissues (43.33%, 13/30) was significantly higher than in adjacent tissues (13.33%, 4/30, χ2= 4.948, P=0.026). ROC curve analysis confirmed that CXCL8 had good diagnostic efficacy for colon cancer (AUC=0.89, 95%CI: 0.85-0.93), with higher diagnostic value in stage Ⅲ-Ⅳ patients (AUC=0.92). The high expression group of CXCL8 showed significantly shorter overall survival (HR=1.79, P<0.001) and disease-specific survival (HR=2.21, P<0.001). Multivariate Cox regression analysis showed that high expression of CXCL8 was an independent prognostic risk factor for colon cancer patients (HR=1.93, 95%CI: 1.04-3.58, P=0.037). The nomogram based on CXCL8 predicted 1-year, 3-year, and 5-year survival rates with AUCs of 0.837, 0.821, and 0.792, respectively. Conclusions CXCL8 is highly expressed in colon cancer, with both diagnostic and independent prognostic predictive value. It promotes the progression of colon cancer by remodeling the immune microenvironment and activating pro-cancer pathways, making it a potential biomarker for precise diagnosis and treatment of colon cancer.

       

      • HTML全文
      • 参考文献(13)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回